6 patents currently held
33 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2033. from the record
Of the 33 now held by other companies, 17 name Knoa Pharma LLC as their current owner, and 16 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2033
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2038 · High confidence
Also notable
Ends Dec 2033 · High confidence
Also notable
Ends May 2039 · Low confidence
Pharmaceutical Compositions for the Treatment of Ophthalmic Conditions
US 11,786,463
Granted 2023. Computed term ends 2038.
Systems and Methods for Increasing Stability of Dronabinol Compositions
US 10,624,859
A family of 5 related applications built on the 2020 grant. Protection runs to 2033.
Compositions and Dosage Forms for Oral Delivery
US 12,419,896
Granted 2025. Too new for citation comparison; protection runs to 2039. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends May 2034 · High confidence
Cited by 10 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2034.
now held by Knoa Pharma LLC
Also notable
Ends Mar 2036 · High confidence
Cited by 15 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2036.
now held by Noramco, LLC
Also notable
Ends Nov 2033 · High confidence
Cited by 10 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2033.
now held by Knoa Pharma LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 17, 2027The maintenance fee for Pharmaceutical Compositions for the Treatment of Ophthalmic Conditions (US 11,786,463) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 1 fee due Oct 21, 2027The maintenance fee for Systems and Methods for Increasing Stability of Dronabinol Compositions (US 10,624,859) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compositions and Dosage Forms for Oral Delivery | 2 in force | to May 2039 |
| Pharmaceutical Compositions for the Treatment of Ophthalmic Conditions | 2 in force | to Aug 2038 |
| Systems and Methods for Increasing Stability of Dronabinol Compositions | 2 in force | to Jan 2034 |
Patents held now
Soonest term end first.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,624,859 | Systems and Methods for Increasing Stability of Dronabinol Compositions In force · High confidence | In force | High confidence | |
| US 11,571,392 | Systems and Methods for Increasing Stability of Dronabinol Compositions In force · High confidence | In force | High confidence | |
| US 11,786,463 | Pharmaceutical Compositions for the Treatment of Ophthalmic Conditions In force · High confidence | In force | High confidence | |
| US 12,396,948 | Pharmaceutical Compositions for the Treatment of Ophthalmic Conditions In force · High confidence | In force | High confidence | |
| US 12,011,430 | Compositions and Dosage Forms for Oral Delivery In force · High confidence | In force | High confidence | |
| US 12,419,896 | Compositions and Dosage Forms for Oral Delivery In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 6: 33 patents in force now held by others · 17 patents ended · 4 applications pending · 29 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.